RU2020142530A - Множественные олигонуклеотидные фрагменты на пептидном носителе - Google Patents
Множественные олигонуклеотидные фрагменты на пептидном носителе Download PDFInfo
- Publication number
- RU2020142530A RU2020142530A RU2020142530A RU2020142530A RU2020142530A RU 2020142530 A RU2020142530 A RU 2020142530A RU 2020142530 A RU2020142530 A RU 2020142530A RU 2020142530 A RU2020142530 A RU 2020142530A RU 2020142530 A RU2020142530 A RU 2020142530A
- Authority
- RU
- Russia
- Prior art keywords
- aon
- peptide
- rxrrbr
- glu
- naturally occurring
- Prior art date
Links
- 239000012634 fragment Substances 0.000 title claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 2
- 108091034117 Oligonucleotide Proteins 0.000 title 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 36
- 238000012230 antisense oligonucleotides Methods 0.000 claims 36
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 34
- 238000000034 method Methods 0.000 claims 14
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims 6
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims 6
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 102100021158 Double homeobox protein 4 Human genes 0.000 claims 4
- 101000968549 Homo sapiens Double homeobox protein 4 Proteins 0.000 claims 4
- 102000018658 Myotonin-Protein Kinase Human genes 0.000 claims 4
- 108010052185 Myotonin-Protein Kinase Proteins 0.000 claims 4
- 108091093037 Peptide nucleic acid Proteins 0.000 claims 4
- 108010009583 Transforming Growth Factors Proteins 0.000 claims 4
- 102000009618 Transforming Growth Factors Human genes 0.000 claims 4
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical group NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims 4
- 230000000295 complement effect Effects 0.000 claims 4
- 108020004999 messenger RNA Proteins 0.000 claims 4
- -1 methylene methylimino Chemical group 0.000 claims 4
- 239000002213 purine nucleotide Substances 0.000 claims 4
- 238000003776 cleavage reaction Methods 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000007017 scission Effects 0.000 claims 3
- NTPQDQNDQNWGFV-UHFFFAOYSA-N (morpholin-4-ylamino)phosphonic acid Chemical compound OP(O)(=O)NN1CCOCC1 NTPQDQNDQNWGFV-UHFFFAOYSA-N 0.000 claims 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical group NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims 2
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims 2
- 101710159080 Aconitate hydratase A Proteins 0.000 claims 2
- 101710159078 Aconitate hydratase B Proteins 0.000 claims 2
- 102100033676 CUGBP Elav-like family member 1 Human genes 0.000 claims 2
- 229930028154 D-arginine Natural products 0.000 claims 2
- 125000002038 D-arginyl group Chemical group N[C@@H](C(=O)*)CCCNC(=N)N 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 108010001483 Glycogen Synthase Proteins 0.000 claims 2
- 102100039264 Glycogen [starch] synthase, liver Human genes 0.000 claims 2
- 102100039262 Glycogen [starch] synthase, muscle Human genes 0.000 claims 2
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 claims 2
- 101000944448 Homo sapiens CUGBP Elav-like family member 1 Proteins 0.000 claims 2
- 101001036117 Homo sapiens Glycogen [starch] synthase, liver Proteins 0.000 claims 2
- 101001036130 Homo sapiens Glycogen [starch] synthase, muscle Proteins 0.000 claims 2
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 claims 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims 2
- 108010006035 Metalloproteases Proteins 0.000 claims 2
- 102000005741 Metalloproteases Human genes 0.000 claims 2
- 108700011259 MicroRNAs Proteins 0.000 claims 2
- 108091092724 Noncoding DNA Proteins 0.000 claims 2
- 102000004264 Osteopontin Human genes 0.000 claims 2
- 108010081689 Osteopontin Proteins 0.000 claims 2
- 108091005804 Peptidases Proteins 0.000 claims 2
- 102000035195 Peptidases Human genes 0.000 claims 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 2
- 102000044126 RNA-Binding Proteins Human genes 0.000 claims 2
- 101710105008 RNA-binding protein Proteins 0.000 claims 2
- 229960002684 aminocaproic acid Drugs 0.000 claims 2
- 229940000635 beta-alanine Drugs 0.000 claims 2
- 125000002091 cationic group Chemical group 0.000 claims 2
- RTINQKRHLKCKBZ-UHFFFAOYSA-N diaminophosphinic acid;morpholine Chemical group NP(N)(O)=O.C1COCCN1 RTINQKRHLKCKBZ-UHFFFAOYSA-N 0.000 claims 2
- 230000014509 gene expression Effects 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 239000002679 microRNA Substances 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 claims 2
- 150000003212 purines Chemical class 0.000 claims 2
- 239000002719 pyrimidine nucleotide Substances 0.000 claims 2
- 150000003230 pyrimidines Chemical class 0.000 claims 2
- 102000005600 Cathepsins Human genes 0.000 claims 1
- 108010084457 Cathepsins Proteins 0.000 claims 1
- 229930182847 D-glutamic acid Natural products 0.000 claims 1
- 125000004077 D-glutamic acid group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C([H])([H])C([H])([H])C(N([H])[H])=O 0.000 claims 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims 1
- 102000001039 Dystrophin Human genes 0.000 claims 1
- 108010069091 Dystrophin Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102000004142 Trypsin Human genes 0.000 claims 1
- 108090000631 Trypsin Proteins 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 235000019833 protease Nutrition 0.000 claims 1
- 235000019419 proteases Nutrition 0.000 claims 1
- 239000012588 trypsin Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
- C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (37)
1. Способ лечения заболевания или состояния субъекта, включающий введение конъюгата пептид-антисмысловой олигонуклеотид (пептид-AON) субъекту,
где конъюгат пептид-AON содержит катионный проникающий в клетку пептид (CPP) и по меньшей мере два антисмысловых олигонуклеотида (AON), где каждый AON содержит:
(a) от 15 до 30 субъединиц фосфордиамидатного морфолинового олигомера (PMO), пептидной нуклеиновой кислоты (PNA), морфолино, фосфорамидата, метиленметилимино (MMI), 2-O-метил (2-OMe), или 2-метилэтила (2-MOE); где каждая субъединиа содержит встречающееся в природе пуриновое или пиримидиновое основание, выбранное из группы, состоящей из C, G, A и T;
(b) последовательность нуклеотидных оснований, комплементарную по меньшей мере 8 смежным основаниям пре-мРНК мишени, мРНК, микроРНК или длинной некодирующей ДНК гена;
(c) от 0 до 3 повторяющихся субъединиц, где встречающееся в природе пуриновое нуклеотидное основание представляет собой G;
(d) менее чем 60% указанных субъединиц, где встречающееся в природе пуриновое или пиримидиновое нуклеотидное основание представляет собой C или G; и
(e) не комплементарную самой себе последовательность, и
где заболевание или состояние связано с экспрессией гена, и ген выбирают из группы, состоящей из гликогенсинтазы (GYS1 или GYS2), трансформирующего фактора роста (TGF3), матриксной металлопептидазы (MMP2 или MMP9), остеопонтина, протеинкиназы миотонической дистрофии (DMPK), 2 члена семейства Elav-подобных (также известного как триплетный CUG-повтор РНК-связывающего белка или CUGBP), двойного гомеобокса 4 (DUX4) и (Frzl).
2. Способ модуляции экспрессии гена гена-мишени у субъекта, включающий введение конъюгата пептид-антисмысловой олигонуклеотид (пептид-AON) субъекту,
где конъюгат пептид-AON содержит катионный проникающий в клетку пептид (CPP) и по меньшей мере два антисмысловых олигонуклеотида (AON), где каждый AON содержит:
(a) от 15 до 30 субъединиц фосфордиамидатного морфолинового олигомера (PMO), пептидной нуклеиновой кислоты (PNA), морфолино, фосфорамидата, метиленметилимино (MMI), 2-O-метил (2-OMe), или 2-метилэтила (2-MOE); где каждая субъединиа содержит встречающееся в природе пуриновое или пиримидиновое основание, выбранное из группы, состоящей из C, G, A и T;
(b) последовательность нуклеотидных оснований, комплементарную по меньшей мере 8 смежным основаниям пре-мРНК мишени, мРНК, микроРНК или длинной некодирующей ДНК гена;
(c) от 0 до 3 повторяющихся субъединиц, где встречающееся в природе пуриновое нуклеотидное основание представляет собой G;
(d) менее чем 60% указанных субъединиц, где встречающееся в природе пуриновое или пиримидиновое нуклеотидное основание представляет собой C или G; и
(e) не комплементарную самой себе последовательность.
3. Способ по п. 2, где ген-мишень выбирают из группы, состоящей из гликогенсинтазы (GYS1 или GYS2), трансформирующего фактора роста (TGF3), матриксной металлопептидазы (MMP2 или MMP9), остеопонтина, протеинкиназы миотонической дистрофии (DMPK), 2 члена семейства Elav-подобных (также известного как триплетный CUG-повтор РНК-связывающего белка или CUGBP), двойного гомеобокса 4 (DUX4) и (Frzl).
4. Способ по п. 1 или 2, где ген кодирует дистрофин.
5. Способ по п. 1, где заболевание или состояние представляет собой мышечную дистрофию Дюшенна.
6. Способ по п. 1 или 2, где CPP содержит (RXR)4 или (RXRRBR)2, где R означает D-аргинин, X означает 6-аминогексановую кислоту, и B означает β-аланин.
7. Способ по п. 1 или 2, где конъюгат пептид-AON содержит по меньшей мере один расщепляемый линкер, содержащий пептидную последовательность, которая содержит расщепляемый фрагмент для гидролитического фермента.
8. Способ по п. 7, где указанный расщепляемый фрагмент может расщепляться пептидазой или протеазой.
9. Способ по п. 7 или 8, где расщепляемый фрагмент может расщепляться катепсином или трипсином.
10. Способ по п. 9, где расщепляемый фрагмент представляет собой FK или FX в положении P1/P1’, где X представляет собой любую встречающуюся в природе аминокислоту.
11. Способ по п. 1 или 2, где конъюгат пептид-AON выбирают из группы, состоящей из:
(i) Ac-(RXR)4XFKE-((PEG)2-AON)G-(AON));
(ii) Ac-(RXRRBR)2XFKE(AON)G(AON);
(iii) Ac-(RXRRBR)2XFD(d-Glu)(AON)E(AON)G(AON);
(iv) Ac-E(AON)(RXRRBR)2XFKE(AON)G(AON);
(v) Ac-E(AON)(RXRRBR)2XFK(d-Glu)(AON)E(AON)G(AON);
(vi) Ac-(d-Glu)(AON)E(AON)(RXRRBR)2XFKG-амид;
(vii) Ac-(d-Glu)(AON)E(AON)(RXRRBR)2XFKG(AON);
(viii) Ac-(d-Glu)(AON)E(AON)(RXRRBR)2XFKE(AON)G(AON); и
(ix) Ac-(d-Glu)(AON)E(AON)(RXRRBR)2XFK(d-Glu)(AON)E(AON)G(AON),
где Ac представляет собой ацетил, R представляет собой D-аргинин, X представляет собой 6- аминогексановую кислоту, B представляет собой β-аланин, E представляет собой глутаминокую кислоту, d-Glu представляет собой D-глутаминовую кислоту, и G представляет собой глицин.
12. Способ по любому из пп. 1-11, где каждый AON представляет собой PMO.
13. Способ по п. 12, где PMO представляет собой PMO23 (SEQ ID NO:85).
14. Способ по п. 12 или 13, где один PMO конъюгирован с CPP через амидную связь.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462002296P | 2014-05-23 | 2014-05-23 | |
US62/002,296 | 2014-05-23 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2016150629A Division RU2739987C2 (ru) | 2014-05-23 | 2015-05-22 | Множественные олигонуклеотидные фрагменты на пептидном носителе |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2020142530A true RU2020142530A (ru) | 2021-04-26 |
Family
ID=53366294
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2016150629A RU2739987C2 (ru) | 2014-05-23 | 2015-05-22 | Множественные олигонуклеотидные фрагменты на пептидном носителе |
RU2020142530A RU2020142530A (ru) | 2014-05-23 | 2015-05-22 | Множественные олигонуклеотидные фрагменты на пептидном носителе |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2016150629A RU2739987C2 (ru) | 2014-05-23 | 2015-05-22 | Множественные олигонуклеотидные фрагменты на пептидном носителе |
Country Status (15)
Country | Link |
---|---|
US (2) | US20170182171A1 (ru) |
EP (1) | EP3151841B1 (ru) |
JP (2) | JP6825914B2 (ru) |
KR (1) | KR102487942B1 (ru) |
CN (1) | CN106459975B (ru) |
AR (1) | AR101542A1 (ru) |
AU (1) | AU2015263963B2 (ru) |
BR (1) | BR112016027236A2 (ru) |
CA (1) | CA2949104C (ru) |
IL (1) | IL249064B (ru) |
MX (1) | MX2016015156A (ru) |
RU (2) | RU2739987C2 (ru) |
SG (2) | SG10202004611SA (ru) |
TW (1) | TWI726844B (ru) |
WO (1) | WO2015179742A1 (ru) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2739987C2 (ru) | 2014-05-23 | 2020-12-30 | Джензим Корпорейшн | Множественные олигонуклеотидные фрагменты на пептидном носителе |
JP7441455B2 (ja) * | 2017-09-22 | 2024-03-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイト | 筋ジストロフィーの処置のためのチオモルホリノオリゴヌクレオチド |
WO2019170731A1 (en) | 2018-03-07 | 2019-09-12 | Sanofi | Nucleotide precursors, nucleotide analogs and oligomeric compounds containing the same |
US10758629B2 (en) * | 2018-05-29 | 2020-09-01 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
JP2022547888A (ja) * | 2019-09-05 | 2022-11-16 | サノフイ | ヌクレオチド類似体を含有するオリゴヌクレオチド |
WO2021211572A1 (en) * | 2020-04-14 | 2021-10-21 | Oregon State University | Antisense therapeutics for the treatment of coronavirus |
EP4387676A2 (en) * | 2021-09-03 | 2024-06-26 | Sarepta Therapeutics, Inc. | Delivery of anitsense oligomers by mirror image peptides |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7634694A (en) * | 1993-08-20 | 1995-03-21 | University Of Medicine And Dentistry Of New Jersey | Bridged polycationic polymer-oligonucleotide conjugates and methods for preparing same |
DE19935302A1 (de) | 1999-07-28 | 2001-02-08 | Aventis Pharma Gmbh | Konjugate und Verfahren zu deren Herstellung sowie deren Verwendung zum Transport von Molekülen über biologische Membranen |
AU2004235396B2 (en) | 2003-04-29 | 2010-11-25 | Sarepta Therapeutics, Inc. | Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells |
AU2008271050B2 (en) | 2007-06-29 | 2014-11-06 | Sarepta Therapeutics, Inc. | Tissue specific peptide conjugates and methods |
US20100016215A1 (en) | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
WO2009144481A2 (en) | 2008-05-30 | 2009-12-03 | Isis Innovation Limited | Conjugates for delivery of biologically active compounds |
WO2009147368A1 (en) | 2008-06-04 | 2009-12-10 | Medical Research Council | Peptides |
CA3066050A1 (en) | 2008-10-24 | 2010-04-29 | Sarepta Therapeutics, Inc. | Multiple exon skipping compositions for dmd |
WO2012177639A2 (en) * | 2011-06-22 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Bioprocessing and bioproduction using avian cell lines |
DK2756080T3 (da) * | 2011-09-14 | 2019-05-20 | Translate Bio Ma Inc | Multimeriske oligonukleotidforbindelser |
TWI677350B (zh) * | 2012-09-25 | 2019-11-21 | 美商健臻公司 | 治療強直性肌失養症之經胜肽連結之嗎啉基反義寡核苷酸 |
JP2017505623A (ja) * | 2014-01-30 | 2017-02-23 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 生物切断性コンジュゲートを有するポリオリゴマー化合物 |
RU2739987C2 (ru) | 2014-05-23 | 2020-12-30 | Джензим Корпорейшн | Множественные олигонуклеотидные фрагменты на пептидном носителе |
-
2015
- 2015-05-22 RU RU2016150629A patent/RU2739987C2/ru active
- 2015-05-22 CN CN201580027369.4A patent/CN106459975B/zh active Active
- 2015-05-22 SG SG10202004611SA patent/SG10202004611SA/en unknown
- 2015-05-22 US US15/313,405 patent/US20170182171A1/en not_active Abandoned
- 2015-05-22 MX MX2016015156A patent/MX2016015156A/es unknown
- 2015-05-22 EP EP15727795.5A patent/EP3151841B1/en active Active
- 2015-05-22 AR ARP150101604A patent/AR101542A1/es unknown
- 2015-05-22 BR BR112016027236A patent/BR112016027236A2/pt active Search and Examination
- 2015-05-22 WO PCT/US2015/032142 patent/WO2015179742A1/en active Application Filing
- 2015-05-22 RU RU2020142530A patent/RU2020142530A/ru unknown
- 2015-05-22 CA CA2949104A patent/CA2949104C/en active Active
- 2015-05-22 JP JP2016567889A patent/JP6825914B2/ja active Active
- 2015-05-22 KR KR1020167035607A patent/KR102487942B1/ko active IP Right Grant
- 2015-05-22 SG SG11201608880VA patent/SG11201608880VA/en unknown
- 2015-05-22 TW TW104116447A patent/TWI726844B/zh active
- 2015-05-22 AU AU2015263963A patent/AU2015263963B2/en active Active
-
2016
- 2016-11-20 IL IL249064A patent/IL249064B/en unknown
-
2019
- 2019-02-01 US US16/265,883 patent/US11103587B2/en active Active
-
2021
- 2021-01-13 JP JP2021003149A patent/JP7269968B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
CA2949104C (en) | 2023-09-26 |
US20190388547A1 (en) | 2019-12-26 |
JP7269968B2 (ja) | 2023-05-09 |
MX2016015156A (es) | 2017-03-27 |
CN106459975A (zh) | 2017-02-22 |
EP3151841B1 (en) | 2022-10-19 |
TW201617373A (zh) | 2016-05-16 |
JP2021063128A (ja) | 2021-04-22 |
JP2017517253A (ja) | 2017-06-29 |
KR20170005118A (ko) | 2017-01-11 |
AR101542A1 (es) | 2016-12-28 |
EP3151841A1 (en) | 2017-04-12 |
WO2015179742A1 (en) | 2015-11-26 |
RU2016150629A (ru) | 2018-06-25 |
AU2015263963B2 (en) | 2021-02-18 |
CA2949104A1 (en) | 2015-11-26 |
TWI726844B (zh) | 2021-05-11 |
KR102487942B1 (ko) | 2023-01-11 |
US11103587B2 (en) | 2021-08-31 |
AU2015263963A1 (en) | 2016-12-01 |
JP6825914B2 (ja) | 2021-02-03 |
CN106459975B (zh) | 2020-03-27 |
SG11201608880VA (en) | 2016-11-29 |
RU2739987C2 (ru) | 2020-12-30 |
SG10202004611SA (en) | 2020-06-29 |
RU2016150629A3 (ru) | 2018-12-24 |
US20170182171A1 (en) | 2017-06-29 |
BR112016027236A2 (pt) | 2017-10-17 |
IL249064A0 (en) | 2017-01-31 |
IL249064B (en) | 2021-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2020142530A (ru) | Множественные олигонуклеотидные фрагменты на пептидном носителе | |
Lundin et al. | Biological activity and biotechnological aspects of peptide nucleic acid | |
Hussain et al. | A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides | |
JP2015529469A5 (ru) | ||
Ganesh et al. | Peptide nucleic acids analogs and derivatives | |
AU2005299306B2 (en) | Antisense antiviral compound and method for treating influenza viral infection | |
Brognara et al. | Peptide nucleic acids targeting miR-221 modulate p27Kip1 expression in breast cancer MDA-MB-231 cells | |
Patutina et al. | miRNases: Novel peptide-oligonucleotide bioconjugates that silence miR-21 in lymphosarcoma cells | |
Moccia et al. | Insights on chiral, backbone modified peptide nucleic acids: properties and biological activity | |
WO2006078217A1 (en) | COMPLEX CONTAINING SiRNA, ShRNA OR ANTISENSE MOLECULE AND FUNCTIONAL ENTITY, FOR IMPROVED SPECIFICITY AND DELIVERY | |
JP2013510584A5 (ru) | ||
US20210371861A1 (en) | Multi-Targeting Nucleic Acid Constructs Composed Of Multiple Oligonucleotides That Modulate Gene Expression Through Complimentary Interactions With Targets | |
Patutina et al. | Peptide-oligonucleotide conjugates exhibiting pyrimidine-X cleavage specificity efficiently silence miRNA target acting synergistically with RNase H | |
KR101026502B1 (ko) | 마이크로rna 안티센스 pna, 그를 포함하는 조성물, 및 그의 사용 및 평가 방법 | |
US20220411841A1 (en) | Methods of synthesizing rna molecules | |
JPWO2019074110A1 (ja) | 一本鎖核酸分子およびその製造方法 | |
US20150315581A1 (en) | Signal activatable constructs and related components compositions methods and systems | |
JP2017517253A5 (ru) | ||
Bhingardeve et al. | Cγ (S/R)-Bimodal peptide nucleic acids (Cγ-bm-PNA) form coupled double duplexes by synchronous binding to two complementary DNA strands | |
Williams et al. | Peptidyl–Oligonucleotide Conjugates Demonstrate Efficient Cleavage of RNA in a Sequence-Specific Manner | |
Arzumanov et al. | A structure-activity study of the inhibition of HIV-1 Tat-dependent trans-activation by mixmer 2′-O-methyl oligoribonucleotides containing locked nucleic acid (LNA), α-L-LNA, or 2′-thio-LNA residues | |
Fokina et al. | Analysis of new charge-neutral DNA/RNA analogues phosphoryl guanidine oligonucleotides (PGO) by gel electrophoresis | |
US11555189B2 (en) | Antisense oligomer compounds | |
Patil et al. | Recognition of RNA sequence and structure by duplex and triplex formation: targeting miRNA and pre-miRNA | |
WO2021231305A3 (en) | Viral delivery vehicle selection |